ArriVent BioPharma, Inc. (AVBP) stock
AVBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.69−0.87 (-7.53%)
Close on Nov 17, 2026Market cap $527.10MP/E –Yield –
ArriVent BioPharma operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
ArriVent BioPharma's operating cash flow for the twelve months ending Jun 30, 2026 was -$147.93M. For fiscal 2025 it was -$160.59M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$160.59M | – |
| FY2024 | Dec 31, 2024 | -$70.21M | – |
| FY2023 | Dec 31, 2023 | -$55.84M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$39.58M | – |
| Q1 FY2026 | Mar 31, 2026 | -$41.89M | – |
| Q4 FY2025 | Dec 31, 2025 | -$30.66M | – |
| Q3 FY2025 | Sep 30, 2025 | -$35.80M | – |
| Q2 FY2025 | Jun 30, 2025 | -$26.12M | – |
| Q1 FY2025 | Mar 31, 2025 | -$68.01M | – |
| Q4 FY2024 | Dec 31, 2024 | -$16.15M | – |
| Q3 FY2024 | Sep 30, 2024 | -$16.35M | – |
| Q2 FY2024 | Jun 30, 2024 | -$19.09M | – |
| Q1 FY2024 | Mar 31, 2024 | -$18.63M | – |
| Q4 FY2023 | Dec 31, 2023 | -$14.91M | – |
| Q3 FY2023 | Sep 30, 2023 | -$15.44M | – |
| Q2 FY2023 | Jun 30, 2023 | -$8.61M | – |
| Q1 FY2023 | Mar 31, 2023 | -$16.88M | – |
See a number that looks wrong?